Functional Evidence for P2X Receptors in Isolated Human Vagus Nerve

Philip M. Lang, M.D.,* Wolfgang Sippel,† Stefan Schmidbauer, M.D.,‡ Dominik Irnich, M.D.,§ Peter Grafe, M.D., Ph.D.¶

IONOTROPIC adenosine 5'-triphosphate (ATP) (P2X) receptors are expressed in some primary afferent neurons, and activation of these receptors results in membrane depolarisation. Many studies indicate that one subtype, the P2X₃ receptor, may contribute to the transduction of nociceptive stimuli in somatosensory² and visceral afferents.^{3,4} However, the function of this receptor in the peripheral human nervous system is poorly understood. Using sensory testing, pain was experienced on local application of ATP on a human blister base preparation⁵ or by iontophoresis of ATP to human skin.⁶ However, it was not possible to identify the subtype of purinergic receptor underlying this effect. In the current study, we have used a new human nerve preparation. We tested the sensitivity of isolated fascicles of human vagus nerve to agonists at P2X₃ receptors. It is known that persistent changes in membrane potential and axonal excitability occur during application of the P2X3 receptor agonist α,β -methylene ATP (α,β -meATP) to rat nodose ganglion cells, 1 to isolated rat vagus nerve^{7,8} and in single vagal afferents in the mouse.9 Our data indicate that isolated fascicles of human vagus nerve can be used to study the pharmacology of P2X3 receptors in the peripheral human autonomic nervous system.

Materials and Methods

Preparations

The experiments on human vagus nerves were conducted using 12 isolated fascicles from four patients. Approval for this procedure was obtained from the Ethics Committee of the University of Munich, and the patients gave written informed consent. The patients (male, n=4) were aged 49, 55, 66, and 69 yr when they underwent the procedure. All of them underwent complete surgical resection of the stomach because of cancer. A 2- to 3-cm part of the anterior vagal trunk at the distal abdominal esophagus (subdiaphragmatic) was removed from the area of gastrectomy.

Experimental Setup

Experimental procedures were done as described previously. ¹⁰ Briefly, isolated human nerve fascicles nerves were held at each end by suction electrodes in an organ bath. One suction electrode was used to elicit action potentials; the other was used as a recording electrode. The distance between stimulating and recording electrodes was approximately 3 mm. The organ bath (volume, 2 ml) was continuously perfused with solution at a flow rate of 6–8 ml/min (32°C). The perfusion solution contained (in mM) NaCl 118, KCl 3.0, CaCl₂ 1.5, MgCl₂ 1.0, D-glucose 5.0, NaHCO₃ 25, and NaH₂PO₄ 1.2, and it was bubbled with 95% O₂/5% CO₂ (pH 7.4).

Electrophysiologic Recordings

Isolated fascicles of human vagus nerve were stimulated with a linear stimulus isolator (A395, WPI, Sarasota, FL) with 1.0-ms current pulses ($100-500~\mu A$) at a frequency of 1 Hz. The stimulator was controlled by a computer via a data acquisition board (Data Translation DT2812, Marlboro MA). Compound action potentials were elicited and recorded, making use of the QTRAC program (copyright, Hugh Bostock, Ph.D., Professor, Institute of Neurology, London, United Kingdom). The peak amplitude of the C-fiber component was measured continuously from the negative to the positive maximum.

Intracellular Calcium Concentration

Cells in the nerve fascicles were loaded with membrane-permeant esters of the fluorescent dyes Calcium Green-1 and Fura Red. The organ bath containing the nerve fascicles was mounted on an inverted fluorescence microscope (Zeiss Axiovert 35, Jena, Germany) with a custom-made photometric attachment and was illuminated at 0.33Hz with 10-ms light pulses at 485 nm. Intensity of the emitted fluorescent light was measured after filtering by two photodiodes at 530 nm (Calcium Green) and 660 nm (Fura Red). Emission intensities were recorded using the QTRAC program. The ratio of the two emission intensities was calculated off-line to give a measure of intracellular calcium concentration.

Chemicals

 α,β -meATP (α,β -methylene-adenosine 5'-triphosphate), Ap5A (diadenosine pentaphosphate), ATP (adenosine 5'-triphosphate), and ATP γ S (adenosine 5' [γ -thio] triphosphate) were purchased from Sigma (St. Louis, MO). Trinitrophenyl (TNP)-ATP (2' (or 3')-O-adenosine 5'-

^{*} Postdoctoral Fellow, § Staff Anesthesiologist, Department of Anesthesiology, * Postdoctoral Fellow, † Medical Student, ¶ Professor, Department of Physiology, ‡ Staff Surgeon, Department of Surgery, University of Munich.

Received from the Departments of Anesthesiology, Physiology, and Surgery, University of Munich, Munich, Germany. Submitted for publication November 15, 2002. Accepted for publication February 27, 2003. Supported by Deutsche Forschungsgemeinschaft (SFB 391/A1), Bonn, Germany.

Address reprint requests to Dr. Lang: Department of Anesthesiology, University of Munich, Nussbaumstr. 20, Munich 80336, Germany. Address electronic mail to: philip.lang@ana.med.uni-muenchen.de. Individual article reprints may be purchased through the Journal Web site, www.anesthesiology.org.

LABORATORY REPORT 233




Fig. 1. Effects of α,β -methylene-adenosine 5'-triphosphate $(\alpha,\beta-meATP)$ on the peak amplitude of the C-fiber compound action potential in isolated human vagus nerve. Continuous recordings of the peak amplitude are shown on the left, and individual compound action potentials taken before and after application of α,β -meATP to the bathing solution are shown on the right. α,β -meATP was tested in ascending concentrations on a single fascicle.

triphosphate), Calcium Green-1, and Fura Red were purchased from Molecular Probes (Eugene, OR). MRS 2179 (2'-deoxy-N⁶-methyladenosine 3',5'-bisphosphate) was purchased from Tocris (Bristol, UK). Agonists at purinergic receptors were administered for 2–4 min with application-free intervals of at least 10 min after recovery to baseline. TNP-ATP and MRS 2179 were usually given 10 min before application of the agonists.

Statistical Analysis

Data are given as deviation from the resting "peak amplitude" and the intracellular Ca^{2+} baseline, both set as 100% (mean \pm SD).

Results

Compound action potentials of unmyelinated axons (C-fiber component) were recorded from isolated fascicles of human vagus nerve during repetitive electrical stimulation at 1 Hz. Agonists and one antagonist at P2X receptors were applied via the bathing solution and tested on the peak amplitude of the C-fiber compound action potentials. A representative experiment is illustrated in figure 1. α,β -meATP was tested in concentrations from 1 to 30 μ M, and a reduction in compound action potential amplitude was observed. Quantitatively (mean \pm SD), α,β -meATP in a concentration of 1 μ M did not change the peak amplitude, whereas a reduction in peak amplitude was observed in concentrations of 3 μ M




Fig. 2. Pharmacologic profile of ionotropic adenosine 5'-triphosphate (P2X) receptors of unmyelinated axons in isolated human vagus nerve. Changes in the peak amplitude of the C fiber compound action potential are shown. The agonists $(\alpha, \beta$ -meATP, Ap5A, ATP- γ -S) and one antagonist (TNP-ATP) at P2X receptors were applied via the bathing solution. The *inset* shows a representative example of the C fiber compound action potential following the stimulus artifact (stimulus duration: 1 ms).

 $(-9.6 \pm 4.8\%, \text{ n} = 3), 10 \ \mu\text{M} (-18.6 \pm 10.3\%, \text{ n} = 3), 20 \ \mu\text{M} (-12.3 \pm 3.3\%, \text{ n} = 9), \text{ and } 30 \ \mu\text{M} (-20.1 \pm 9.7\%, \text{ n} = 3).$

In further experiments, other agonists at P2X receptors were tested. Reduction in peak amplitude was also observed by using Ap5A (45 μ M) and ATP γ S (100 μ M). These compounds reduced the amplitude of the C-fiber compound action potential by 8.4 \pm 2.9% (n = 3) and 14.1% (n = 2), respectively. The effects of α , β -meATP (n = 4), Ap5A (n = 2), and ATP γ S (n = 1) were completely blocked in the presence of 20 μ M TNP-ATP (fig. 2).

In additional experiments, application of ATP (100 μ M) to the bathing solution induced a rapid and transient rise in intracellular Ca²⁺. Quantitatively, ATP (100 μ M) increased the emission ratio of Calcium Green/Fura Red by 19.4 \pm 10.8% (n = 7). MRS 2179 (20 μ M), an antagonist at P2Y₁ receptors, blocked the ATP-induced intracellular Ca²⁺ transient (fig. 3).

Discussion

The data indicate that recordings from isolated fascicles of human vagus nerve can be used for functional studies of P2Y and P2X receptors in the peripheral human nervous system. To our knowledge, this is the first optical and electrophysiologic study on an isolated human vagus nerve preparation. The presence of P2Y receptors in human peripheral nerve has already been demonstrated using ATP-induced Ca²⁺ transients in isolated sural nerve. ^{10,11} Schwann cells are most likely the

234 LABORATORY REPORT




Fig. 3. Changes in the free intracellular Ca²⁺ concentration in a fascicle of human vagus nerve. The nerve fascicle was loaded with the Ca²⁺-sensitive fluorescent dyes Calcium Green and Fura Red. An increase in the emission ratio e(530 nm)/ e(660 nm) indicates an increase in [Ca²⁺]_i. ATP produces an increase in [Ca²⁺]_i. MRS 2179 antagonizes the intracellular Ca²⁺ transient.

cellular elements causing these intracellular Ca²⁺ transients.¹² In the current study, ATP-induced Ca²⁺ transients were also found in isolated human vagus nerve (fig. 3). These Ca²⁺ transients were blocked by MRS 2179, a potent antagonist at P2Y₁ receptors.¹³ This indicates that P2Y receptors are functional in both somatosensory and visceral human nerves.

To our knowledge, electrophysiologic evidence for the activity of P2X receptors in the peripheral human nervous system has not been described, except for the observation that α,β -meATP induces contraction of muscle specimen from human bladder.¹⁴ In the current study, clear effects of agonists at P2X receptors were found on action potentials of unmyelinated axons in segments of human vagus nerve. The pharmacologic profile indicates the presence of P2X3 and/or heteromeric $P2X_{2/3}$ receptors, because α,β -meATP is an agonist and TNP-ATP is an antagonist at these subtypes of P2X receptor. 15-17 P2X receptors in human vagus nerve were also activated by the less specific P2X receptor agonists Ap5A¹⁸ and ATPγS. Recently, desensitization of P2X₃ receptors by low concentrations of Ap5A has been described. 19 This effect was not tested in the current study. It is known that P2X receptors depolarize neurons. We therefore interpret the changes in compound action potentials as a consequence of axonal depolarization in the human vagus nerve (e.g., due to inactivation of sodium channels).

In previous studies, effects of ATP on afferent human nerve fibers have been observed using microneurography²⁰ and sensory testing. In the latter case, pain was experienced on local application of ATP on a human blister base preparation⁵ or by iontophoresis of ATP to human skin.⁶ However, in intact nervous tissue, there is rapid enzymatic degradation of ATP to adenosine,²¹ and the effects of ATP seen in these studies might have been caused by activation of adenosine/P1 receptors. In fact, the effects of ATP on the excitability of unmyelinated axons in isolated segments of human sural nerve were blocked by adenosine receptor antagonists; evidence for activation of P2X receptors (using α,β -meATP) was not found.^{10,22} The effectiveness of α,β -meATP on human

vagus nerve (current study) and its ineffectiveness on human sural nerve 10 might be attributable to the expression of heteromultimeric $P2X_{2/3}$ receptors in human vagus nerve and homomeric $P2X_3$ receptors in human sural nerve. In this case, bath application of α,β -meATP is sufficient for activation of slowly desensitizing $P2X_{2/3}$ receptors 16 and is probably too slow for the activation of rapidly desensitizing $P2X_3$ receptors.

The function of P2X receptors on unmyelinated afferent nerve fibers in the vagus nerve is not well understood. There is evidence that 80-85% of the vagal nerve fibers are afferent.²³ Mice lacking P2X₃ receptors have marked urinary bladder hyporeflexia, 24,25 and it is plausible that a similar mechanosensory function may be found for P2X receptors in reflex control of distension of the esophagus and/or stomach. 4,9 Models of visceral pain were not investigated in P2X3 knock-out mice. However, TNP-ATP blocks acetic acid-induced abdominal constriction in mice, which indicates a contribution of P2X₃ and heteromeric P2X_{2/3} receptors to inflammatory visceral pain.³ A possible function of P2X receptors in vomiting, emesis, and digestion should be explored. More selective, stable, and bioavailable P2X receptor antagonists might be helpful in such studies and in the treatment of visceral pain.26 Studies on isolated segments of human vagus nerve could be useful in such investigations.

The authors thank Klaus Hallfeldt, M.D., Ph.D., and Thomas Mussack, M.D. (Staff Surgeons, Department of Surgery, University of Munich, Germany), for preparation of the vagus nerve; Christina Müller (Laboratory Technician, Department of Physiology, University of Munich) for technical assistance; and David J. Tracey, Ph.D. (Professor, Department of Anatomy, University of New South Wales, Sydney, Australia), for helpful discussions on the manuscript.

References

- 1. Dunn PM, Zhong Y, Burnstock G: P2X receptors in peripheral neurons. Prog Neurobiol 2001; $65{:}107{-}34$
- 2. Hamilton SG, McMahon SB: ATP as a peripheral mediator of pain. J Auton Nerv Syst 2000; 81:187-94
- 3. Honore P, Mikusa J, Bianchi B, McDonald H, Cartmell J, Faltynek C, Jarvis MF: TNP-ATP, a potent P2X3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics. Pain 2002: 96:99-105
- 4. Burnstock G: Potential therapeutic targets in the rapidly expanding field of purinergic signalling. Clin Med 2002; 2:45-53
- Bleehen T, Keele CA: Observations on the algogenic actions of adenosine compounds on the human blister base preparation. Pain 1977; 3:367-77
- 6. Hamilton SG, Warburton J, Bhattacharjee A, Ward J, McMahon SB: ATP in human skin elicits a dose-related pain response which is potentiated under conditions of hyperalgesia. Brain 2000; 123(Pt 6):1238-46
- 7. Trezise DJ, Kennedy I, Humphrey PP: The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by alpha, beta-methylene adenosine 5'-triphosphate. Br J Pharmacol 1994; 112:282-8
- Irnich D, Burgstahler R, Bostock H, Grafe P: ATP affects both axons and Schwann cells of unmyelinated C fibres. Pain 2001; 92:343-50
- 9. Page AJ, Martin CM, Blackshaw LA: Vagal mechanoreceptors and chemoreceptors in mouse stomach and esophagus. J Neurophysiol 2002; 87:2095–103
- 10. Lang PM, Tracey DJ, Irnich D, Sippel W, Grafe P: Activation of adenosine and P2Y receptors by ATP in human peripheral nerve. Naunyn Schmiedebergs Arch Pharmacol 2002; 366:449-57
- 11. Wachtler J, Mayer C, Quasthoff S, Adelsberger H, Grafe P: P2 purinoceptor-mediated intracellular ${\rm Ca^{2+}}$ transients in human sural nerve. Neuroreport 1996; 7:1289–92
- 12. Mayer C, Quasthoff S, Grafe P: Confocal imaging reveals activity-dependent intracellular ${\rm Ca}^{2+}$ transients in nociceptive human C fibres. Pain 1999; 81:317-22

LABORATORY REPORT 235

- 13. von Kügelgen I, Wetter A: Molecular pharmacology of P2Y-receptors. Naunyn Schmiedebergs Arch Pharmacol 2000; 362:310-23
- 14. O'Reilly BA, Kosaka AH, Knight GF, Chang TK, Ford AP, Rymer JM, Popert R, Burnstock G, McMahon SB: P2X receptors and their role in female idiopathic detrusor instability. J Urol 2002; 167:157-64
- $15.\,$ North RA, Surprenant A: Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol 2000; 40:563–80
- 16. Thomas S, Virginio C, North RA, Surprenant A: The antagonist trinitrophenyl-ATP reveals co-existence of distinct P2X receptor channels in rat nodose neurones. J. Physiol 1998; 509(Pt 2):411-7
- 17. Spelta V, Jiang LH, Surprenant A, North RA: Kinetics of antagonist actions at rat P2X2/3 heteromeric receptors. Br J Pharmacol 2002; 135:1524-30
- 18. Miras-Portugal MT, Gualix J, Mateo J, Diaz-Hernandez M, Gomez-Villafuertes R, Castro E, Pintor J: Diadenosine polyphosphates, extracellular function and catabolism. Prog Brain Res 1999; 120:397–409
- 19. McDonald HA, Chu KL, Bianchi BR, McKenna DG, Briggs CA, Burgard EC, Lynch KJ, Faltynek C, Cartmell J, Jarvis MF: Potent desensitization of human P2X3 receptors by diadenosine polyphosphates. Eur J Pharmacol 2002; 435:135–42

- 20. Hilliges M, Weidner C, Schmelz M, Schmidt R, Orstavik K, Torebjork E, Handwerker H: ATP responses in human C nociceptors. Pain 2002; 98:59-68
- 21. Zimmermann H: Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000; 362:299-309
- 22. Irnich D, Tracey DJ, Polten J, Burgstahler R, Grafe P: ATP stimulates peripheral axons in human, rat and mouse: Differential involvement of A(2B) adenosine and P2X purinergic receptors. Neuroscience 2002; 110:123-9
- 23. Janig W, Habler HJ: Physiology and pathophysiology of visceral pain. Schmerz 2002; 16:429-46
- 24. Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, Novakovic S, Malmberg AB, Cain G, Berson A, Kassotakis L, Hedley L, Lachnit WG, Burnstock G, McMahon SB, Ford AP: Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 2000; 407:1011–5
- 25. Burnstock G: Purine-mediated signalling in pain and visceral perception. Trends Pharmacol Sci 2001; 22:182-8
- 26. Jacobson KA, Jarvis MF, Williams M: Purine and pyrimidine (P2) receptors as drug targets. J Med Chem 2002; 45:4057-93